Fulzerasib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, fulzerasib selectively targets, binds to and inhibits the activity of the KRAS G12C mutant, thereby inhibiting KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - FULZERASIB - GFH 925 - GFH-925 - GFH925 - IBI 351 - IBI-351 - IBI351 - KRAS G12C Inhibitor GFH925 - KRAS G12C Inhibitor IBI351